| Drug | Trial Design | NCT Number | Outcome |
| Tiragolumab | CITYSCAPE: Atezolizumab + Tiragolumab vs. Atezolizumab, Phase II (N = 135), NSCLC | NCT03563716 | mPFS: 5.6 vs. 3.9 months, for patients with PD-L1 ≥ 50%: NR vs. 4 months. |
| Tiragolumab | SKYSCRAPER-01: Similar design as CITYSCAPE in NSCLC, Phase III (N = 635) | NCT04294810 | Trial failed to meet its primary endpoint. |
| Tiragolumab | SKYSCRAPER-02: EP chemotherapy + Atezolizumab and Tiragolumab vs. EP chemotherapy + Atezolizumab, Phase III, SCLC (N = 400) | NCT04256421 | Trial failed to meet its primary endpoint. |
| Tiragolumab | SKYSCRAPER-03: Tiragolumab + Atezolizumab vs. Duravalumab following radio-chemotherapy (Stage III NSCLC, N = 800), Phase III | NCT04513925 | ongoing |
| Tiragolumab | SKYSCRAPER-04: Tiragolumab + Atezolizumab vs. Atezolizumab in cervical cancer (N = 172, Phase III) | NCT04300647 | active, but not recruiting |
| Tiragolumab | SKYSCRAPER-05: Tiragolumab + Atezolizumab, platinum-based chemotherapy, Surgery, Tiragolumab, Atezolizumb vs. Platinum-based chemotherapy, Surgery, Platinum-based Chemotherapy (Phase II, N = 83) | NCT04832854 | ongoing |
| Tiragolumab | SYKSCRAPER-06: Atezolizumab + Tiragolumab plus Pemetrexate/Platinum vs. Pembrolizumab + Pemetrexate/Platinum (N = 500, NSCLC), Phase II | NCT04619797 | ongoing |
| Tiragolumab | SKYSCRAPER-07: Tiragolumab plus Atezolizumab vs. Atezolizumab following radio-chemotherapy (esophageal cancer, N = 750), Phase III | NCT04543617 | ongoing |
| Vibostolimab | KEYVIBE-002: Vibostolimab + Pembrolizumab + Docetaxel vs. Vibostolimab + Pembrolizumab vs. Docetaxel (Phase II, N = 240, NSCLC) | NCT04725188 | ongoing |
| Vibostolimab | KEYVIBE-003: Vibostolimab + Pembrolizumab vs. Pembrolizumab (Phase III, NSCLC, N = 1,246) | NCT04738487 | ongoing |
| Vibostolimab | KEYVIBE-006: Vibostolimab + Pembrolizumab followed by radio-chemotherapy and Vibostolimab + Pembrolizumab vs. radio-chemotherapy followed by Durvalumab (NSCLC, N = 784, Phase III) | NCT05298423 | ongoing |
| Vibostolimab | KEYVIBE-007: Vibostolimab + Pembrolizumab + Chemotherapy vs. Pembrolizumab + Chemotherapy (Phase III, NSCLC, N = 700) | NCT05226598 | ongoing |
| Vibostolimab | KEYVIBE-008: Vibostolimab + Pembrolizumab + EP chemotherapy vs. Atezolizumab + EP chemotherapy (SCLC, Phase III, N = 450) | NCT05224141 | ongoing |
| Domvanalimab | ARC-7: Zimberelimab vs. Zimberelimab + Domvanalimab vs. Zimberelimab + Domvanalimab + Entrumadenant (Phase II, N = 150, NSCLC) | NCT04791839 | ongoing |
| Domvanalimab | PACIFIC-8: Durvalumab + Domvanalimab following radio-chemotherapy (NSCLC, N = 860, interventional) | NCT05211895 | ongoing |
| Ociperlimab | AdvanTIG-301: Ociperlimab + Tislelizumab + concurrent chemo-radiotherapy followed by Ociperlimab or Tislelizumab + concurrent chemo-radiotherapy followed by Tislelizumab versus concurrent chemo-radiotherapy followed by Durvalumab in locally advanced and previously untreated and unresectable NSCLC (N = 900) | NCT04866017 | ongoing |
| Ociperlimab | AdvanTIG-302: Ociperlimab + Tislelizumab versus Pembrolizumab + Placebo (NSCLC, first-line, Phase III, N = 600) | NCT04746924 | ongoing |